A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.

Dasari, Arvind; Hamilton, Erika P; Falchook, Gerald S; Wang, Judy S; Li, Daneng; Sung, Max W; Chien, Caly; Nanda, Shivani; Tucci, Christopher; Hahka-Kemppinen, Marjo; Paulson, Andrew Scott

Dasari, Arvind; Hamilton, Erika P; Falchook, Gerald S; Wang, Judy S; Li, Daneng; Sung, Max W; Chien, Caly; Nanda, Shivani; Tucci, Christopher; Hahka-Kemppinen, Marjo; Paulson, Andrew Scott.

Afiliação

Dasari A; MD Anderson Cancer Center, Houston, TX, USA. ADasari@mdanderson.org.
Hamilton EP; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
Wang JS; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.
Li D; City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
Sung MW; Tisch Institute at The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Chien C; HUTCHMED International Corporation, Florham Park, NJ, USA.
Nanda S; HUTCHMED International Corporation, Florham Park, NJ, USA.
Tucci C; HUTCHMED International Corporation, Florham Park, NJ, USA.
Hahka-Kemppinen M; HUTCHMED International Corporation, Florham Park, NJ, USA.
Paulson AS; Baylor Sammons Cancer Center, Dallas, TX, USA.

Invest New Drugs ; 41(3): 421-430, 2023 Jun.

Article em En | MEDLINE | ID: mdl-37074571

Assuntos

Neoplasias; Tumores Neuroectodérmicos Primitivos; Tumores Neuroendócrinos; Humanos; Tumores Neuroendócrinos/tratamento farmacológico; Tumores Neuroendócrinos/patologia; Receptor 1 de Fatores de Crescimento do Endotélio Vascular; Fator A de Crescimento do Endotélio Vascular; Neoplasias/patologia; Inibidores de Proteínas Quinases/efeitos adversos; Tumores Neuroectodérmicos Primitivos/induzido quimicamente; Dose Máxima Tolerável

Palavras-chave

Extrapancreatic neuroendocrine tumors; Pancreatic neuroendocrine tumors; Surufatinib; Vascular endothelial growth factor receptor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tumores Neuroendócrinos / Tumores Neuroectodérmicos Primitivos / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google